40045-50-9
40045-50-9 結構式
基本信息
5-((5-硝基噻唑-2-基)硫基)-1,3,4-噻二唑-2-胺
2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑
SU 3327
JNK Inhibitor XIII - CAS 40045-50-9 - Calbiochem
5-[(5-Nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine
5-((5-Nitrothiazol-2-yl)thio)-1,3,4-thiadiazol-2-amine
2-Amino-5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazole
1,3,4-Thiadiazol-2-amine, 5-[(5-nitro-2-thiazolyl)thio]-
5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine
JNK,Thiadiazole,SU-3327,TNF-α,Inhibitor,inhibit,SU 3327,p38α,SU3327,insulin,phosphorylation,substrate-competitive,JIP,protein-protein,PPI
物理化學性質
常見問題列表
IC50: 0.7 μM (JNK); 239 nM (JNK-JIP interactions)
SU3327 (compound 9) is able to inhibit TNF-α stimulated phosphorylation of c-Jun in HeLa cells (EC
50
= 6.23 μM).
SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1.
SU3327 (Compound 9; 25 mg/kg; intraperitoneal injection; male BKS.Cg-+Lepr
db
/+Lepr
db
/OlaHsd db/db mice) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes.
SU3327 (Compound 9) has favorable microsomal and plasma stability (T
1/2
= 27 min).
| Animal Model: | Male BKS.Cg-+Lepr db /+Lepr db /OlaHsd db/db mice (11-week-old ) injected with insulin |
| Dosage: | 25 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Resulted in a statistically significant reduction in blood glucose levels. |